median progression-free survival (PFS; 31 months) compared with MPR followed by placebo maintenance (14 months; hazard ratio, 0.49; p Ͻ 0.001) or melphalan and prednisone (MP) followed by placebo maintenance (13 months; hazard ratio, 0.40; p Ͻ 0.001) in patients with newly diagnosed multiple myeloma (NDMM) aged Ն 65 years [1] . Th e benefi t was observed primarily in patients aged 65 -75 years [1, 2]. Health-related quality of life (HRQoL) was a predefi ned secondary endpoint of the MM-015 trial, and the analysis included determination of the minimal important diff erence (MID), which can identify clinically meaningful changes in HRQoL scores [3] . Th e results indicated that clinically meaningful improvements in HRQoL scores were more common in the MPR-R group than in the MPR and MP groups [4] . Th e present analysis expands on these fi ndings. Th e objectives were to identify factors that predict diff erences in HRQoL score levels, and compare HRQoL status at baseline and during treatment with HRQoL status at time of treatment discontinuation due to progressive disease (PD) or discontinuation (DC) for other reasons. HRQoL determinants were derived for the overall patient group (aged Ն 65 years) and the subset of patients aged 65 -75 years.
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Materials and methods

Study design
Th is multicenter phase III randomized study was designed to evaluate the effi cacy and safety of MPR-R in transplantineligible patients with NDMM aged Ն 65 years. Study details have been previously published [1] . Briefl y, patients were randomized (1:1:1) to MPR-R (nine 4-week cycles
Introduction
In the pivotal phase III MM-015 trial, the melphalan, prednisone and lenalidomide regimen, followed by lenalidomide maintenance therapy (MPR-R) signifi cantly increased of melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy); MPR (nine 4-week cycles of melphalan, prednisone and lenalidomide, followed by placebo maintenance therapy); or MP (nine 4-week cycles of melphalan, prednisone and placebo, followed by placebo maintenance therapy) [ Figure 1 (A)]. Th e primary objective was to compare PFS in the MPR-R and MP groups. Patients were stratifi ed according to age (65 -75 vs. Ͼ 75 years) and International Staging System (ISS) stage (I/II vs. III). Treating physicians and patients were unaware of the treatment assignment. Patients received maintenance therapy until PD or DC. All patients were followed for Ն 5 years from randomization or until death. Th e study was conducted in compliance with the Independent Review Board/Independent Ethics Committee procedures, the Declaration of Helsinki, the International Conference on Harmonization, Good Clinical Practices guidelines and local regulations governing the conduct of clinical studies (ClinicalTrials.gov identifi er NCT00405756).
HRQoL assessment
For the HRQoL assessments the new consolidated standards of reporting trials (CONSORT) guidelines for patient reported outcomes (PROs) were used [5] . Th e HRQoL assessments were undertaken using two European Organisation for Research and Treatment of Cancer (EORTC) validated questionnaires: the generic 30-item EORTC QLQ-C30 [6] , and the 20-item EORTC QLQ-MY20 [7] specifi cally designed for patients with multiple myeloma. Th e EORTC QLQ-C30 and QLQ-MY20 questionnaires were available in paper form . ISS, International Staging System; MP, melphalan, prednisone and placebo followed by maintenance therapy with placebo; MPR, melphalan, prednisone and lenalidomide followed by maintenance therapy with placebo; MPR-R, melphalan, prednisone and lenalidomide followed by maintenance therapy with lenalidomide; PBO, placebo; po, by mouth.
in the primary languages spoken at MM-015 study sites. Th e 30 items are scored in fi ve functional domains (Physical Functioning, Emotional Functioning, Cognitive Functioning, Social Functioning and Role Functioning) where a higher score indicates better function. Eight domains assess symptoms (Fatigue, Nausea/Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation and Diarrhea) and one assesses Financial Diffi culties, where a lower score indicates fewer symptoms or fi nancial diffi culties. Th e EORTC QLQ-C30 also contains an item on overall Global Health Status/QoL (subsequently referred to as Global QoL), where a higher score indicates better overall QoL. Th e QLQ-MY20 is a 20-item questionnaire that includes two functional domains (Future Perspective and Body Image) and two symptom domains (Disease Symptoms and Side Eff ects of Treatment), each scored similarly to the QLQ-C30. Each instrument takes approximately 10 -15 min to complete [6, 7] .
Th e HRQoL questionnaires were completed at baseline, after every third treatment cycle (i.e. at the start of cycles 4, 7, 10, 13 and 16, etc.) and at PD or DC. Follow-up included HRQoL assessment every 6 months (168 days) during the open-label extension phase. Results are presented for six prespecifi ed HRQoL domains, selected for up-front analysis based on their perceived clinical relevance: Global QoL, Physical Functioning, Fatigue and Pain from the EORTC QLQ-C30; and Disease Symptoms and Side Eff ects of Treatment from the EORTC QLQ-MY20 [4] . Scores were calculated if Ն 50% of boxes for the items in that particular domain were fi lled according to standard handling of missing or incomplete data [8] .
Compliance of the HRQoL was assessed and previously described for patients enrolled in this study [4] . A patient was considered compliant when at least 50% of the questionnaire items were completed. Th e overall compliance during treatment until cycle 16 was high: Ͼ 76% for each instrument and at least 65% at PD or DC, and were consistent across treatment arms. Th e patient and disease characteristics of patients who dropped out or were not compliant were similar between treatment arms [4] .
Identifi cation of MID
Clinically meaningful changes in HRQoL were defi ned as MIDs and were assessed by calculating the standard error of measurement (SEM), an error estimate for a single use of the questionnaire at baseline [9, 10] . Th e SEM is directly related to the variability of the data through its standard deviation, and the reliability of the scale, as indicated by Cronbach ' s alpha (i.e. SEM ϭ standard deviation ϫ √ 1 Ϫ Cronbach ' s alpha). Th e SEM is considered a good estimate of the MID, being the smallest amount of change from baseline that indicates a clinically meaningful change in HRQoL [11] . MIDs for the six prespecifi ed HRQoL domains have been identifi ed [4] . 
Statistical methods
Analyses were conducted on the intent-to-treat (ITT) population using data collected until the time of un-blinding of the fi rst study site (May 2010), which occurred after the fi rst planned interim analysis [1] . Measurements included baseline and fi ve subsequent time points (cycles 4, 7, 10, 13 and 16). Patients with valid data at each assessment were included in the analysis. Analyses were conducted on data up to the cycle at which each study arm had Ն 30 participants (cycle 16). All analyses were performed using SAS ® version 9.22 (SAS Institute Inc., Cary, NC).
A mixed-eff ects model was developed for predicting HRQoL scores (EORTC QLQ-C30: Global QoL, Physical Regression β -coeffi cients, p -values (based on a t -test statistic that examines whether or not the β -coeffi cient is statistically diff erent from zero) and 95% confi dence intervals were calculated from these models. Th e β -coeffi cients for continuous variables represented the eff ect on HRQoL score for each unit change (i.e. each additional year for age, and each additional score point for baseline HRQoL). Based on an alpha level of 0.05, these results determined statistically signifi cant β -coeffi cients for each of the variables (i.e. determinants of HRQoL). For each of the six preselected HRQoL scores, clinically meaningful eff ects of each variable were assessed by examining whether the β -coeffi cient exceeded the MID [4] .
A separate analysis was conducted based on the subset of patients who had PD or DC prior to cycle 16, which included the following comparisons: (i) HRQoL at end of treatment versus baseline; and (ii) HRQoL during treatment versus end of treatment. For the end of treatment versus baseline comparison, patients were included if they belonged to the ITT population, were randomized to MPR-R, MPR or MP treatment, had PD or DC prior to cycle 16, and had nonmissing scores at baseline and end of treatment. Statistical signifi cance was assessed for the diff erence between mean baseline score and mean PD/DC score within treatment group from a paired t -test statistic.
For the during-treatment versus end of treatment comparison, patients were included if they belonged to the ITT population, were randomized to MPR-R, MPR or . Among patients assigned to MPR-R ( n ϭ 152), MPR ( n ϭ 153) or MP ( n ϭ 154), similar proportions of patients were female (53%, 48% and 51%, respectively), had ISS stage III disease (48%, 48% and 51%, respectively) and were aged Ͼ 75 years (24%, 24% and 25%, respectively).
Determinants of HRQoL: patients aged Ն 65 years
Predictive factors for HRQoL, based on data from 404 patients in the ITT population treated with MPR-R, MPR or MP, are presented in Table I . Choice of treatment (MPR-R vs. MP and MPR vs. MP) had no statistical or clinical significant eff ect on the six HRQoL domains, indicating that the addition of lenalidomide to MP with lenalidomide maintenance therapy did not adversely aff ect HRQoL. Achieving Ն VGPR (vs. SD) was associated with statistically significant improvement for all six domain scores and the MID was exceeded in the Global QoL score. With the exception of a slight improvement in Side Eff ect of Treatment, achieving PR (vs. SD) had no eff ect on HRQoL scores. Having PD was associated with a statistically signifi cant and clinically meaningful deterioration in Global QoL and a statistically signifi cant (but not clinically meaningful) worsening of Physical Functioning, Fatigue, Pain and Disease Symptoms. Deterioration in Global QoL and Physical Functioning due to DC was statistically signifi cant but not clinically meaningful. Anemia grade 3 -4 had a statistically signifi cant and clinically meaningful negative impact on Global QoL, Physical Functioning, Fatigue and Side Eff ects of Treatment. Disease Symptoms was also negatively aff ected, but the MID was not reached. Neutropenia grade 3 -4 had no eff ect on HRQoL scores.
MP treatment, had PD or DC prior to cycle 16, and had non-missing scores for end of treatment and at least one treatment cycle excluding baseline. A mixed model was developed where the patient was specified as the random effect and cycle as a fixed effect. From this model, mean HRQoL was calculated across all during-treatment HRQoL scores and at PD or DC for each treatment group. Statistical significance for the difference between mean HRQoL scores at end of treatment and during treatment within treatment group was assessed with a t -test statistic produced from the model.
To minimize the eff ects of multiple testing associated with baseline, during treatment and end of treatment analyses in patients who had PD or DC, statistical signifi cance was assessed after a Bonferroni adjustment was applied to p -values. Th at is, the statistical signifi cance level was established at 0.017 by dividing 0.05 by the number of treatment groups ( n ϭ 3). Th erefore, p -values Յ 0.017 were considered statistically signifi cant.
Role of the funding source
Th e trial was designed by the academic authors in collaboration with Celgene. Employees of the company assisted with the study design, data collection, data analysis and writing of the manuscript in collaboration with the senior academic authors. Th e fi rst draft of the manuscript was developed by the authors. All authors had full access to all the data on study un-blinding and had fi nal responsibility for the decision to submit the manuscript for publication. Assistance in manuscript preparation was provided by ICON Clinical Research, Oxford Outcomes and Excerpta Medica, which was funded by Celgene. All authors were fully responsible for all content and editorial decisions for this manuscript and vouch for the accuracy and completeness of the data and the fi delity of the study to the protocol. 
Determinants of HRQoL: patients aged 65 -75 years
Th e second set of mixed-eff ects models for the subset of patients aged 65 -75 years ( n ϭ 316) indicated a similar pattern with regard to factors that infl uence HRQoL (Table II) 
HRQoL scores at PD or DC versus during treatment
Diff erences in mean HRQoL scores, between during treatment and end of treatment due to PD or DC, are presented in Figure 2 . In patients receiving MP, HRQoL was signifi cantly better during treatment versus the time of PD/DC for Global QoL ( p Ͻ 0.001; n ϭ 59) and Physical Functioning ( p ϭ 0.001; n ϭ 58); the diff erence was also clinically meaningful for 
Discussion
Th is analysis of HRQoL data from trial MM-015 was undertaken to identify predictors of HRQoL and compare HRQoL scores at baseline or during therapy with those at the time of PD or DC. Th e results suggest that female gender, advanced age and development of PD negatively aff ect HRQoL, whereas better HRQoL scores at baseline and better response to treatment ( Ն VGPR) were associated with improvements in HRQoL. Better response ( Ն VGPR) was more frequently observed with MPR-R than with MP (33% vs. 12%), whereas PD was observed less often with MPR-R than with MP (PFS hazard ratio 0.40; p Ͻ 0.001) [1] . DC, which was more commonly observed in the MPR-R group than in the MP group (43% vs. 23%) [1] , had a statistically signifi cant but no clinically meaningful eff ect on HRQoL. Neutropenia grade 3 -4 was found to not exert any signifi cant infl uence on HRQoL. Anemia grade 3 -4, which occurred at a similar incidence in the MPR-R and MP groups (24% vs. 14%, respectively; p ϭ 0.091), negatively aff ected some HRQoL domains. Findings in the subset of patients aged 65 -75 years were generally consistent with the overall fi ndings in patients aged Ͼ 65 years. Taken together, these data show that the addition of lenalidomide to MP with subsequent lenalidomide maintenance therapy had no adverse eff ect on HRQoL, and that . Statistical signifi cance was determined after applying a Bonferroni adjustment for multiple treatments. Italicized text means that the MID was achieved. DC, discontinuation (for any reason other than progressive disease); HRQoL, health-related quality of life; MID, minimal important diff erence; MP, melphalan, prednisone and placebo followed by maintenance therapy with placebo; MPR-R, melphalan, prednisone and lenalidomide followed by maintenance therapy with lenalidomide; PD, progressive disease.
to the remaining group of HRQoL domains [4] . Th is study has shown a clear negative association between HRQoL and PD, whereby PD was defi ned as a laboratory progression in accordance with the European Group for Blood and Marrow Transplantation criteria [1] . In clinical practice it is conceivable that patients would be treated until symptom relapse according to CRAB criteria ([elevated] calcium, renal failure, anemia, bone lesions); these associations were not tested here due to heightened levels of complexity. However, this reinforces the importance of the fi ndings in this publication and indicates that there may be an even stronger negative correlation between HRQoL and symptom progression.
Lastly, although the inclusion of neutropenia and anemia in our mixed-eff ects model provides interesting observations, a more detailed analysis of the relationship between adverse events and HRQoL may provide further insights into this area of research.
Conclusion
Based on the MM-015 NDMM population, several factors were identifi ed that predicted HRQoL, including achievement of VGPR (which was associated with improved HRQoL) and PD (which negatively aff ected HRQoL). Th e MPR-R regimen, which has been shown to prolong PFS compared with MP, was associated with several statistically signifi cant and clinically meaningful improvements of HRQoL. Th is suggests that MPR-R is an important MPR-R may positively aff ect HRQoL through achievement of better response and delay in PD.
Patients experienced on average better HRQoL during treatment than at the time of PD, and the diff erence in HRQoL was particularly pronounced in the MPR-R treatment group. However, in no instances were mean HRQoL scores at the time of PD signifi cantly worse than scores at baseline. Th ese fi ndings confi rm the negative impact of PD on HRQoL and underscore the importance of delaying PD in patients with NDMM.
Positive eff ects of MPR-R on HRQoL found in this analysis contrast with recently published data from the VISTA trial, which indicate that use of melphalan, prednisone and bortezomib was associated with a temporary worsening in HRQoL, especially between cycles 3 and 6 [13] . However, it is not possible to directly compare results from MM-015 and VISTA due to diff erences in study design (MM-015 is doubleblind and VISTA is open-label), treatment regimens, study populations and follow-up duration. Th e fi ndings highlight the potential eff ects of treatment on HRQoL and suggest that further studies are needed to directly compare the impact of bortezomib-and lenalidomide-based regimens on HRQoL.
One limitation of this analysis is that it is based on interim data; therefore, an updated analysis using fi nal MM-015 data is recommended. A second limitation could be the preselection of six HRQoL domains. Th is focus was considered justifi able, however, as longitudinal results of these six HRQoL domains have been found to be mostly comparable Figure 3 . Mean HRQoL scores during treatment versus end of treatment (PD) by treatment group. Mean diff erences in scores were added to the x -axis. Bold table entries were statistically signifi cant after applying a Bonferonni adjustment for multiple treatments and/or were clinically meaningful. HRQoL, health-related quality of life; MID, minimal important diff erence; MP, melphalan, prednisone and placebo followed by maintenance therapy with placebo; MPR-R, melphalan, prednisone and lenalidomide followed by maintenance therapy with lenalidomide; PD, progressive disease. for comparisons of multiple treatments of best score versus baseline score ( * ) and best score versus PD score ( ϩ ) within treatment group. HRQoL, health-related quality of life; MP, melphalan, prednisone and placebo followed by maintenance therapy with placebo; MPR, melphalan, prednisone and lenalidomide followed by maintenance therapy with placebo; MPR-R, melphalan, prednisone and lenalidomide followed by maintenance therapy with lenalidomide; PD, progressive disease. treatment option for transplant-ineligible patients with NDMM. HRQoL may be especially relevant in circumstances where a survival advantage is diffi cult to demonstrate, such as in frontline treatment for multiple myeloma, where there is an increasing use of novel agents as salvage therapy. Th e marked deterioration in HRQoL observed at PD in this analysis emphasizes the clinical importance of delaying PD, even in situations where an overall survival advantage has not yet been demonstrated due to a limited number of events.
